ethyl 2-(phenylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate | 101195-64-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(phenylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• 英文别名: ethyl 2-(phenylcarbamoyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate
• CAS: 101195-64-6
• 化学式: C₁₉H₂₀N₂O₃
• 分子量: 324.379
• InChiKey: LNDRIGBAUCXZLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉-3-羧酸乙酯 、 异氰酸苯酯 以 甲苯 为溶剂， 生成 ethyl 2-(phenylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
  参考文献：
  名称：

  Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists

  摘要：

  The design and synthesis of a novel series of Rev-erb alpha agonists is described. The development and optimization of the tetrahydroisoquinoline series was carried out from an earlier acyclic series of Rev-erb alpha agonists. Through the optimization of the scaffold 1, several potent compounds with good in vivo profiles were discovered. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.023

文献信息

• [EN] MODULATORS OF REV-ERB<br/>[FR] MODULATEURS DE REV-ERB
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015103527A1

  公开（公告）日：2015-07-09

  The subject matter herein concerns the identification and development of potent synthetic REV-ERB ligands, such as in vivo agonists and antagonists. These compounds allow for characterization of the effects of modulation of this receptor in vivo specifically on circadian behavior and metabolism, and have suitable characteristics for development of medicinal compounds useful for treatment of malconditions such as diabetes, obesity, atherosclerosis, dyslipidemia, a circadian rhythm disorder, coronary artery disease, bipolar disorder, depression, cancer, a sleep disorder, an anxiety disorder, an addiction disorder, a bone-related disorder such osteoporosis, a skeletal muscle disease, e.g., with compromised exercise capacity, or an autoimmune disorder such as psoriasis, multiple sclerosis, inflammatory bowel disease, and others.

  本文涉及识别和开发强效合成REV-ERB配体，例如体内激动剂和拮抗剂。这些化合物可用于特定在体内对昼夜节律行为和新陈代谢的调节效果进行表征，并具有适合开发用于治疗糖尿病、肥胖症、动脉粥样硬化、血脂异常、昼夜节律紊乱、冠状动脉疾病、躁郁症、抑郁症、癌症、睡眠障碍、焦虑障碍、成瘾障碍、骨相关疾病如骨质疏松症、骨骼肌肉疾病（例如，运动能力受损）、自身免疫性疾病如牛皮癣、多发性硬化、炎症性肠病等疾病的药用化合物的特性。
• Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists
  作者：Romain Noel、Xinyi Song、Youseung Shin、Subhashis Banerjee、Douglas Kojetin、Li Lin、Claudia H. Ruiz、Michael D. Cameron、Thomas P. Burris、Theodore M. Kamenecka

  DOI：10.1016/j.bmcl.2012.04.023

  日期：2012.6

  The design and synthesis of a novel series of Rev-erb alpha agonists is described. The development and optimization of the tetrahydroisoquinoline series was carried out from an earlier acyclic series of Rev-erb alpha agonists. Through the optimization of the scaffold 1, several potent compounds with good in vivo profiles were discovered. (C) 2012 Elsevier Ltd. All rights reserved.